London phone chat trials

If you’re a researcher trying to get information on a trial from a company, you can of institutions, rather than their promises: the proportion of their completed trials for which they have shared results.

Meanwhile, you can read more about the battle for unreported clinical trials at By now I hope you all know about the ongoing global scandal of clinical trial results being left unpublished, and of course our All Trials campaign.

With clinical trials you can make clear rules, you can measure compliance, and you can enforce compliance.

London phone chat trials-42

The results on the individual companies are important, but we also came across some fascinating patterns.

While companies superficially have commitments to register and report clinical trials, in reality, there are often huge gaps in their policies, with many failing to include past trials (trials on the medicines we use today) and trials on off-label uses or unlicensed medicines, which are both important.

Sorry not to be in regular blogging mode at the moment.

Here’s a video of our evidence session to parliament, where they are running an inquiry into research integrity.

This is only part of our story as our scientists and researchers are developing drugs to make life changing difference to peoples lives worldwide.

We continue to work with our long term partner Centre National de la Recherche Scientifique (CNRS), Europe’s largest fundamental research institution and Immu Pharma’s long standing collaboration partner.

We also found a huge of commitments, which is exactly what audits are good for: identify who’s doing well, and who’s doing badly, so that everyone can learn from the best players.

Lastly, as we went along we collected some fascinating examples of problematic policies, ambiguous language, inconsistent commitments, odd exclusions, and so on.

Immu Pharma has the potential of expanding the P140 peptide platform into other auto immune conditions such as: Rheumatoid Arthritis, Crohn’s Disease, and Asthma.

Very few AIM-listed drug development companies have late-stage clinical assets of similar calibre.

Immu Pharma PLC is a pharmaceutical development company focusing on developing novel medicines in specialist markets with serious unmet need.

Tags: , ,